News

Since the first issue of CDR officially published on March 19, 2018, more and more scholars pay attention to this journal and inspired by the journal’s achievement throughout the year. In 2018, CDR has totally published 20 papers of which have been cited 14 times within this year. With the continues support of scholars worldwide, 7 special issues on the topics such as "Pharmacogenetics of cancer", "Non-coding RNAs in Response and Resistance to Therapy in Cancer" and "Drug resistance mechanisms in cancer" etc are open for submission and have broaden the understanding to experts in the field to a certain extent.

We would like to sincerely thank each and every reviewer who dedicated his or her time and expertise to reviewing manuscripts for Cancer drug resistance. In the review process, at least two experts contribute comment about each paper published in CDR, without their help, we would not be as fast-growing as it is today. Thus, the Journal of Cancer Drug Resistance acknowledge with particular gratitude the following reviewers who give freely of their support during the period March 2018-December 2018.

We now offer an article collection of CDR Speical Issues to our authors, which are freely available for download on our website. If you are the Guest Editor of any of these Special Issues, please feel free to contact us for the printed version of the Ebooks. Your kind promotion of this collection through either conferences or other means would be highly appreciated.

For the future development, Cancer Drug Resistance (Cancer Drug Resist) held its first strategic planning symposium on August 26, 2016 and all team members joined it. This meeting aimed to discuss the planning and development strategies by inviting Prof. Peters. According to the orientation of the journal, Prof. Peters said that current academic journals on cancer drugs cover many areas on drug metabolism, pharmacology, drug actions, drug development, biomarkers and many more items, but a specific journal on cancer drug resistance does not exist, except for a general review journal Drug Resistance Update. Therefore, he expects that the planned journal has a great development prospect.